ALKEM5,111.00

Alkem Laboratories Ltd.

· Pharma & Health
₹ CrorePeersMANKINDTORNTPHARMIPCALABLUPINFORTISAUROPHARMALAURUSLABSBIOCONMcap ₹61,102 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt1,214.01,062.81,623.51,623.5
Net Debt609.9-143.6638.3638.3
Total Debt/Equity0.110.090.110.11
Net Debt/Equity0.06-0.010.040.04
Total Debt/EBITDA0.540.420.540.54
Net Debt/EBITDA0.27-0.060.210.21
Interest Coverage (EBIT/Interest)17.3117.7116.3216.32
Total Debt/Total Capital %10.187.8710.1610.16
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.